Liquid Biopsy Guides New Prostate Cancer Drug Trial

07:11 EDT 19 Jun 2017 | Genetic Engineering News

It’s been no secret that screening methods to detect prostate cancer have been woefully lacking and largely inconsistent with respect to the results they provide. Yet, with the rise in validated biomarkers and advanced diagnostics coupled with next-generation sequencing methods, new liquid biopsy assays are guiding physician treatment options. Now, a group of investigators at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have developed a three-in-one blood test that could transform the treatment of advanced prostate cancer through the use of precision drugs designed to target mutations in the BRCA genes. "Blood tests for cancer promise to be truly revolutionary,” noted Paul Workman, Ph.D., chief executive of The Institute of Cancer Research, London. “They are cheap and simple to use, but most importantly, because they aren't invasive, they can be employed or applied to routinely monitor patients to spot early if treatment ...

Original Article: Liquid Biopsy Guides New Prostate Cancer Drug Trial


More From BioPortfolio on "Liquid Biopsy Guides New Prostate Cancer Drug Trial"

Quick Search


Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...

Immunoassay - ELISA
Immunoassays are quick and accurate tests to detect specific molecules. Immunoassays rely on an antibody to bind to the specific structure of a molecule. Antibodies are proteins generated by animals in response to the invasion of a foreign molecule (anti...